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Abstract 1 
Background: The role of lymph node dissection (LND) in renal cell carcinoma (RCC) 2 
is still under debate. We aimed to assess the utilization rates of LND over time in 3 
Europe. 4 
Methods: A multi-institutional database of 13,581 RCC patients who underwent 5 
radical nephrectomy (RN) or nephron sparing surgery (NSS) between 1988 and 2014 6 
was created within an European consortium. We analysed temporal trends in the 7 
frequency of LND by using Joinpoint regression. Logistic regression models were used 8 
to identify predictors of LND. 9 
Results: Overall, 5,114 patients (42.7%) underwent LND. Lymph node invasion was 10 
recorded in 566 cases (11% of LND patients) which represents 4.7% of the whole study 11 
cohort. A gradual decline in the use of LND started in the 1990ies. After 2008 LND 12 
decreased significantly by 21.5% per year (95%CI -33.3 to -7.5, p<0.01) until 2011 and 13 
stabilized thereafter (Annual Percentage Change 4.9%, 95%CI -3.4 to 13.8, p=0.2). At 14 
multivariable analyses, patient age (OR 0.98, p<0.0001), type of surgery (RN vs. NSS: 15 
OR 5.46, p<0.0001), surgical approach (open vs. minimally invasive: OR 1.75, 16 
p<0.0001), T stage (T2 vs. T1: OR 1.57; T3-4 vs. T1: OR 1.44, p<0.0001), clinical 17 
tumour size (OR 1.14, p<0.0001), and year of surgery (OR 0.95, p<0.0001) were 18 
associated with higher probability of LND at nephrectomy.  19 
Conclusions: A trend towards lower LND was observed over time for RCC patients 20 
who underwent RN or NSS. LND is more frequently performed in younger patients, 21 
locally advanced diseases and in case of open surgery.  22 
 3 
Introduction  23 
Surgery is the mainstay of therapy for patients with localised renal cell 24 
carcinoma (RCC) and an integral part of a multimodal therapeutic concept of patients 25 
presenting with metastatic disease [1-3]. The standard of surgical care, nephrectomy 26 
with lymphadenectomy, has been overshadowed by nephron-sparing surgery (NSS) 27 
in the past two decades. Data indicate that NSS is non-inferior to radical nephrectomy 28 
(RN) in terms of oncological outcomes[4], but may be associated with improved overall 29 
survival due to a decreased risk of cardiovascular events during follow-up[5]. 30 
Regional lymph node dissection (LND) is a well-accepted staging modality in 31 
RCC[6] and was traditionally performed from the bifurcation of the aorta to the crus of 32 
the diaphragm [7]. There are, however, limited data that support the therapeutic benefit 33 
of the use of this extended routine LND in clinical practice. Indeed, a randomized 34 
clinical trial demonstrated no survival benefit for performing a LND, but this trial 35 
included mainly patients with early stage disease [8]. Because of lack of high-quality 36 
data supporting its use and the unpredictable lymphatic drainage of RCC, no clear 37 
standards for indications and templates were established [9], and LND rates decreased 38 
dramatically. A publication from the United States showed that LND is currently 39 
performed in only 6.6% of nephrectomies [10]. This decrease has been reinforced by 40 
stage migration towards smaller tumours and the increasing adoption of minimally-41 
invasive surgery [10]. The objective of the current study was to describe temporal 42 
trends and identify predictors of LND in a multicentre European cohort of patients with 43 
RCC.  44 
 4 
Methods 
Study population 
For this retrospective study, all participating sites obtained institutional review 45 
board approval and provided the necessary institutional data sharing agreements 46 
before study initiation. The initial study cohort consisted of 13,581 consecutive patients 47 
with RCC who underwent RN or NSS from 1988 to 2014. No patient had preoperative 48 
systemic therapy. Cases with missing data were excluded (n=1,593, 11.7%), resulting 49 
in a cohort of 11,988 assessable patients.  50 
 51 
Study variables 52 
The collected variables were abstracted from patient charts and included age, 53 
gender, year of surgery, pathological TNM classification, clinical tumour size, treatment 54 
type (NSS vs. RN), surgical approach (open vs. laparoscopic vs. robotics), receipt of 55 
LND, LND template, and number of nodes removed. The database was frozen on 1-56 
July-2016 and the final dataset was produced for current analyses. 57 
 58 
Clinical and pathological TNM classifications were assigned according to the 2009 59 
American Joint Committee on Cancer/Union Internationale Contre le Cancer 60 
definitions (AJCC/UICC) [1]. Cases before the introduction of the most recent 61 
classification scheme were reclassified. Clinical tumour size was based on 62 
preoperative imaging and defined as the greatest tumour diameter in centimetres. 63 
Pathological TNM and LND characteristics (number of positive or negative lymph 64 
nodes) were assessed at the single institution by dedicated expert uro-pathologist 65 
without a systematic central pathological review. 66 
 67 
 5 
Outcome 68 
The outcome of interest was receipt of a LND and the rate of lymph node 69 
invasion (LNI) during RN or NSS.  70 
 71 
Statistical analyses 72 
Frequencies and proportions were reported for categorical variables. Mean, 73 
medians and interquartile ranges (IQR) were calculated for continuously coded 74 
variables. 75 
Temporal trends in the practice pattern of LND were evaluated using a 76 
piecewise regression approach that is implemented in the Joinpoint Regression 77 
Program (Version 4.1, National Cancer Institute, Bethesda, MD, United States). 78 
Joinpoint regression has been utilised to identify temporal trends in epidemiology, but 79 
has been successfully applied to evaluate trends in cancer diagnostics and therapies 80 
[11]. Specifically, the annual frequency of LND was modelled using a linear segmented 81 
regression function, with a log-transformed dependent variable, and inflection points 82 
corresponding to changes of slope. We allowed up to five inflection points, and the 83 
permutation test was used to identify the most parsimonious model. The presence of 84 
an inflection point was interpreted as a change in temporal trend of the use of LND and 85 
are reported as Annual Percentage Change (APC). 86 
We used multivariable logistic regression to estimate the adjusted effects of 87 
each variable on the likelihood of receiving a LND. Covariates included age, year of 88 
surgery, country, pathological T stage, M stage, clinical tumour size, treatment type 89 
(NSS vs. RN), surgical approach [open vs. minimally invasive (laparoscopic or 90 
robotics)]. Adjusted odds ratios (OR), 95% confidence intervals (95% CI), and two-91 
sided p-values were obtained. Similar analyses were repeated in the subgroup of 92 
 6 
patients (n=4,321, 36.0%) with available information regarding the LND template 93 
(anatomical region of LND and number of lymph nodes removed). 94 
Statistical analyses were performed using SPSS version 20 (IBM Corp., 95 
Somers, NY, United States) and the Joinpoint Regression Program (National Cancer 96 
Institute, Bethesda, MD, United States). All tests were two-sided with a significance 97 
level set at p<0.05. 98 
 7 
Results 99 
Table 1 shows the descriptive characteristics of the patients included. Overall, 100 
5,114 of 11,988 patients (42.7%) underwent LND. PN patients underwent LND less 101 
frequently relative to RN counterparts (PN 28.8% vs RN 50.1%, p<0.001). Among 102 
patients treated with LND, pathological LNI was recorded in 566 cases (11.0%), 103 
representing 4.7% of the entire study cohort.  104 
 105 
Temporal trends in LND 106 
A gradual decline in the use of LND started in the 1990ies and dramatically 107 
occurred in 2008 (Figure 1A). Specifically, the proportion of patients who underwent 108 
LND showed an initial but insignificant increase between 1988 and 1990 (APC 10.1%, 109 
95% CI -6.6 to 29.7, p=0.2), followed by a significant decline by 3.6% per year until 110 
2002 (95% CI -4.7 to -2.5, p<0.01). Following an increase by 6.0% between 2002 and 111 
2008 (95% CI 2.2 to 10.0, p<0.01), after 2008 LND decreased significantly by 21.5% 112 
per year (95% CI -33.3 to -7.5, p<0.01) until 2011 and stabilized thereafter (APC 4.9%, 113 
95% CI -3.4 to 13.8, p=0.2).  114 
Changes observed in patients with pT1 disease mirrored findings from the 115 
overall cohort and recently stabilized at around 10% (Figure 2A). LND in pT2 disease 116 
declined between 1988 and 1995 (APC -5.2%, 95% CI -9.8 to -0.3, p<0.01), which was 117 
followed by non-significant changes between 1995 and 2008 (APC 1.5%, 95% CI -0.7 118 
to 3.8, p=0.2). From 2008 to 2014, there was a significant decline (APC -12.4%, 95% 119 
CI -17.8 to 6.6, p<0.01) (Figure 2B). There were no significant changes in the LND rate 120 
among patients with pT3-4 disease (APC 0.1%, p=0.7) (Figure 2C). The LND rate in 121 
M0 disease decreased initially by 1.9% per year (95% CI -2.9 to -0.9, p<0.01), followed 122 
by non-significant changes between 2004 and 2008. From 2008 to 2011, the LND rate 123 
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dropped by 28.9% per year (95% CI -45.5 to -7.1, p<0.01) and stabilized thereafter 124 
(p=0.4) (Figure 2D). No changes in the LND rate were seen in M1 disease (APC -0.3%, 125 
p=0.4) (Figure 2E). 126 
As regards type of surgery and approach, during open surgery, there was a 127 
significant decline in LND between 1988 and 2005 by 2.9% per year (95% CI -3.5 to -128 
2.2, p<0.01). Between 2005 and 2008, there was a marginally significant trend towards 129 
a rising proportion of LND (APC 21.5%, 95% CI -0.1 to 47.8, p=0.07), followed by a 130 
significant decrease (APC -21.0%, 95% CI -35.0 to -0.8, p=0.03) and a recent increase 131 
(APC 10.3%; p=0.05) (Figure 3A). The LND rate during laparoscopic surgery 132 
continuously declined, except between 2005 and 2008 (Figure 3B). During the early 133 
years of adoption, LND was rarely used during robotic surgery. A recent increase was 134 
seen, but this was not statistically significant (p=0.1) (Figure 3C). Among patients who 135 
underwent NSS a significant decline was observed after 2012 (APC -99.5%, p=0.02) 136 
(Figure 3D). During RN, there was an initial increase in LND (APC 18.9%, 95% CI 9.3 137 
to 29.4, p<0.01), followed by non-significant changes until 1999 (p=0.1 and p=0.5, 138 
respectively). After a significant increase between 1999 and 2007 (APC 7.4%, 95% 5.0 139 
to 9.9, p<0.01), LND decreased until 2011 (APC -11.6%, 95% CI -18.7 to -3.8, p<0.01). 140 
There was recent significant increase between 2011 and 2014 (Figure 3E). 141 
There was a statistically significant increase of surgeries in which no LND was 142 
performed (p<0.05 for 1988-1998 and 1998-2014, respectively) (Figure 4A). The rates 143 
of hilar LND declined continuously (APC -3.8%, 95% CI -5.1 to -2.5, p<0.01), similarly 144 
to side-specific LND (APC -3.6%, 95% CI -4.6 to -2.6, p<0.01) (Figure 4B-C). The 145 
extended LND rate decreased significantly until 2001 (APC -14.7%, 95% CI -18.1 to 146 
11.2, p<0.01), and stabilized thereafter at a rate of around 6% (p=0.8) (Figure 4D). 147 
 9 
After 2008, less than 8% of the patients received an extended LND at the time of 148 
nephrectomy. 149 
 150 
Predictors of LND 151 
On multivariable analyses, patient age (OR 0.98, 95% CI 0.97-0.99, p<0.0001), 152 
type of surgery (RN vs. NSS: OR 5.46, 95%CI 5.00-6.63, p<0.0001), surgical approach 153 
(open vs. minimally invasive: OR 1.75, 95%CI 1.43-2.13, p<0.0001), T stage (T2 vs. 154 
T1: OR 1.57 95%CI 1.19-2.07; T3-4 vs. T1: OR 1.44 95%CI 1.20-1.73, p<0.0001), 155 
clinical size (OR 1.14, 95%CI 1.11-1.14, p<0.0001) and year of surgery (OR 0.95, 156 
95%CI 0.94-0.96, p<0.0001) were independent predictors of LND.  157 
 158 
Temporal trends in LNI 159 
Although the percentage of LNI remained stable over time in case of locally-160 
advanced disease (LNI rate: 12% in 1988-1996 vs. 12% in 2008-2014, Figure 5), it 161 
declined in patients with pT1 (LNI rate: 6.2% in 1988-1996 vs. 3.9% in 2008-2014, 162 
Figure 5) or pT2 disease (LNI rate: 1.7% in 1988-1996 vs. 0.4% in 2008-2014, Figure 163 
5). On multivariable analyses adjusted for the effects of patient and tumour 164 
characteristics, year of surgery was not associated with the probability of LNI (p=0.3).  165 
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Discussion 
Although the majority of RCC patients are diagnosed with small organ-confined 166 
disease, up to 40% of patients harbour locally advanced disease or distant metastases 167 
[3]. In these specific scenarios, LNI confirmation has paramount implications for risk 168 
stratification and prognosis. Indeed, LNI remains one of the most informative predictors 169 
of the natural history of the disease, even in the setting of metastatic RCC [12,13]. 170 
Follow-up strategies require precise risk estimation [14] and the lack of a correct nodal 171 
status assessment may underestimate the actual disease burden with critical 172 
consequences for any adjuvant [15] or salvage [6] strategy. 173 
Although some previous reports suggested a potential role in terms of survival 174 
benefit for LND [6,9], the conclusion of the one and only randomized clinical trial [8] 175 
together with the findings of other retrospective studies seem to deny any potential 176 
effect in terms of cancer control [16-18]. More specifically, Gershman et al. evaluated 177 
the association of LND with oncologic outcomes among patients undergoing radical 178 
nephrectomy (RN) for both non-metastatic [16] and metastatic RCC [17]. They 179 
provided evidence that LND was associated with improved oncologic outcomes even 180 
among patients at increased risk of pN1 disease, including those with preoperative 181 
radiographic lymphadenopathy, and after stratification for increasing threshold 182 
probabilities of pN1 disease ranging from 0.05 to 0.50 [16].  183 
Due to the above cited controversies, there are currently no formal guidelines 184 
regarding the extent or nodal template of LND at the time of radical nephrectomy and 185 
the use of LND by urologists was never formally assessed outside the United States. 186 
In such specific geographic setting, Kates and colleagues analysed changes over time 187 
in LND use. In their report, only 6.6% of the patients received LND [10]. There was a 188 
gradual decline in LND beginning in 1988 that accelerated after 1997, with the period 189 
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1998–2005 having significantly decreased odds of LND relative to the period 1988–190 
1997[10]. According to the authors, such a decline was driven by (1) the diffusion of 191 
laparoscopic nephrectomy throughout the US in the late 1990s; (2) the increased use 192 
of cross-sectional imaging in the 1990s led to tumours being identified at a more 193 
localized stage and at a smaller size; (3) an evidenced-based transition because 194 
publications in the late 1990s minimized the importance of LND; (4) the lack of a 195 
discrete common procedural terminology billing code for LND during radical 196 
nephrectomy [10]. 197 
To the best of our knowledge no data assessed the same topic in a European 198 
setting. Therefore, the current study should be regarded as the first formal assessment 199 
of the temporal trends of LND use in RCC and of the relative impact of stage migration 200 
and the introduction of minimally invasive technique on LND utilization rates. Our data 201 
show key aspects regarding LND utilization. First, there was a trend towards lower use 202 
of LND starting in the 1990ies (Figure 1A). A sharp decrease was observed in 2008 203 
(Figure 1A) after the publication of the EORTC trial showing no benefit in terms of 204 
survival. This observation should be regarded as a unique example of the effect of 205 
level 1 evidence on the European Urological community. It is also of note that the 206 
European urologists have applied the EORTC data to organ-confined disease only, 207 
maintaining an elevated percentage of LND in high-risk patients. A little more 208 
worrisome is the drop registered in case of pT2 tumours (LND range 55.8-82.1% 209 
before 2008 vs. 25-54.2% after 2008) considering that the prevalence of LNI among 210 
patients with larger tumours in not negligible [12]. Correspondingly, the percentage of 211 
LNI among T2 cases dropped from 6.8% to 3.9% after the decrease in LND utilization 212 
registered after 2008.  213 
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Second, the current study does report key information about the trend over time 214 
of LND utilization rates according to the type of surgery (NSS vs. RN) and surgical 215 
approach (open vs. laparoscopy vs. robotic), that were lacking in the the report by 216 
Kates and colleagues[10]. The decline in the use of LND was more pronounced among 217 
cases treated with NSS relative to RN (LND range 12.2-33.3% before 2008 vs. 1.8-218 
6.5% after 2008) and among cases treated with laparoscopy relative to open surgery 219 
(LND range 14.7-95.2% before 2008 vs. 14.2-25.7% after 2008). Such important 220 
findings were also confirmed after accounting for different confounders. On the other 221 
hand, due to the intrinsic technical difficulties in performing a retroperitoneal LND 222 
laparoscopically, our findings depict also the potential role of robotic surgery, even in 223 
case of RN, if LND is planned.  224 
Third, besides the declining rate, LND is usually anatomically limited, with only 225 
4.5-8.2% of the patients receiving an extended LND at the time of renal surgery. This 226 
feature is consistent with previous findings suggesting that the majority of LND are 227 
restricted to the hilar area without any drive in terms of further extension[10,19]. 228 
Although the current study represents the first formal assessment of the 229 
temporal trends and the determinants of the use of LND in Europe, is not devoid of 230 
limitations. Since no European population-based database exists to address the topic 231 
also in community hospitals, the current findings are applicable to tertiary care or 232 
academic centres only. Missing information in terms of comorbidities, surgical 233 
expertise and learning curve and disparities among the centers as regards diagnostic 234 
and therapeutic standards might somehow affect the results. Moreover, due to the 235 
multi-institutional nature of the database, it is possible that the protocol for pathological 236 
assessment might be different across all the different center and during the entire study 237 
period.  238 
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Conclusions 239 
A trend towards lower LND was observed over time for RCC patients who 240 
underwent RN or NSS. LND is more frequently performed in younger patients, locally 241 
advanced diseases and in case of open surgery.   242 
 14 
Conflict of interest 243 
None 244 
Acknowledgements 245 
None246 
 15 
Table 1: Descriptive characteristics of the overall cohort (n=11,988, 100%). 
 
Variable  
Age* (years) 62 (60.9) 53-70 
Clinical size* (cm) 5 (5.8) 3-8 
cN 
  0 
  1 
  Missing 
 
75.3% 
8.8% 
15.9% 
M stage (#) 
  M0 
  M1 
 
90.3% 
9.7% 
pT stage (#) 
  T1 
  T2 
  T3-4 
 
57.6% 
9.9% 
32.4% 
pN 
  x 
  0 
  1 
 
53.2% 
42.1% 
4.7% 
Year of surgery*  2002 (2001) 2002-2007 
Treatment type (#) 
  RN  
  NSS 
 
70.9% 
29.1% 
Surgical approach (#) 
  open  
  laparoscopic 
  robotic 
 
79.9% 
19.1% 
1.0% 
*Median (Mean), InterQuartile Range (IQR) 
#Percentage 
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Figures 1A-B: Temporal trend in the use of LND in 11,988 patients undergoing 
RN or NSS. 1A) 95% Confidence Intervals and polynomial trendline are 
reported. 1B) The data markers plot the annual frequencies, and coloured lines 
demonstrate the results of the Joinpoint regression analysis. ^APC was 
significantly different from zero at alpha=0.05. 
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Figures 2A-B-C-D-E: Temporal trends in utilisation of LND in 11,988 patients 
according to T stage (A=pT1, B=pT2, C=pT3-4) and M stage (D=M0, E=M1). ^APC 
was significantly different from zero at alpha=0.05. 
 
  
 18 
Figures 3A-B-C-D-E: Temporal trends in utilisation of LND in 11,988 patients 
according to procedure type (A=open surgery, B=laparoscopic surgery, 
C=robotic surgery, D=nephron-sparing surgery, E=radical nephrectomy). ^APC 
was significantly different from zero at alpha=0.05. 
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Figures 4A-B-C-D: Temporal trends in the utilization of LND in 4,321 patients 
according to the site of LND (A=no LND, B=hilar LND, C=side-specific LND, 
D=extended LND). ^APC was significantly different from zero at alpha=0.05. 
 
 20 
Figure 5: Percentage of patients with pathological confirmation of lymph node 
invasion (LNI, %) stratified for year of surgery and T stage. 
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